PD-1/PD-L1 antibodies have gained clinical approval for the treatment of melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin’s lymphoma, urothelial carcinoma, and gastric cancer10. This evidence concerns the gene PDCD1 and renal cell carcinoma.